OraSure Technologies, Inc.

OraSure Technologies, Inc. is a leading developer and manufacturer of non-invasive diagnostic testing devices and oral specimen collection tools for infectious disease detection. The company's core portfolio includes rapid point-of-care tests for HIV, hepatitis C (HCV), hepatitis B (HBV), syphilis, Ebola, and COVID-19 (InteliSwab). OraSure markets products under multiple brands including OraQuick (rapid antibody tests), SureQuick (rapid tests), and proprietary specimen collection devices. The company also operates through subsidiaries: DNA Genotek (sample collection and preservation solutions for genomic, metabolomic, and microbiome research), Sherlock Biosciences (rapid diagnostic test development), and BioMedomics (sickle-cell rapid testing). Products are distributed globally through direct sales, online ordering, and healthcare provider networks. OraSure serves public health authorities, clinical laboratories, healthcare practitioners, researchers, and retail channels. The company emphasizes accessibility and decentralization of diagnostics, particularly for underserved populations and resource-limited settings. Manufacturing and quality standards align with FDA regulatory requirements and international standards. Customer support includes product training, technical documentation, and dedicated customer care with phone and email channels available for U.S. and international markets.